BioSpace News Archive

Itamar Medical Ltd. reported preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2019 and announced revenue guidance for the full year 2020.

Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks

American Academy of Ophthalmology urges people to get smart about eye health in 2020

New research findings presented in November at the Italian Cancer Society’s 61st annual meeting in Naples, Italy confirm the ability of Phoenix Biotechnology’s drug PBI-05204 to act synergistically with coadministration of temozolamide and radiotherapy to kill Glioblastoma Multiforme in mice with orthotopically implanted human GBM cells.

Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, announced recent progress in its gene therapy programs, including a 12-month update on its Parkinson’s program.

Emergent BioSolutions Inc. announced that it has received agreement from the European Medicines Agency to pursue its proposed development plan for its chikungunya virus virus-like particle vaccine candidate.

Natus Medical Incorporated, a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, reaffirmed fourth quarter 2019 guidance and announced that Jonathan Kennedy, President and Chief Executive Officer will present at the 38th Annual JP Morgan Healthcare Conference in San Francisco.

Submission Based on PAOLA-1 Trial Which Studied LYNPARZA with Bevacizumab in Women Regardless of Their Biomarker Status Who Responded to Platinum-Based Chemotherapy

Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020

Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement